Adalimumab in Tanzania: NEMLIT level, who can prescribe it and STG references

Adalimumab is on Tanzania's National Essential Medicines List (NEMLIT, 7th edition, 2026) at level S (zonal, special and national hospitals). It is not on the DukaDawa pharmacy network yet, so we show no brands or prices for it. The Standard Treatment Guidelines mention it in 8 or more sections.

Last updated

Prescribe on DukadawaRxAsk DukadawaRx AI

New to DukadawaRx? Register as a prescriber. Licensed prescribers only; we verify your registration before you can prescribe.

Is adalimumab available on the DukaDawa pharmacy network?

Not yet. Adalimumab is not in the DukaDawa network catalogue, so we have no brands, prices or stock for it.

Prescribers can still write it on a DukadawaRx prescription, and we show it here as soon as a network pharmacy lists it.

Is adalimumab on the NEMLIT, and who can prescribe it?

Yes. Adalimumab is on Tanzania's National Essential Medicines List (NEMLIT, 7th edition, 2026) at level S (zonal, special and national hospitals). At level S it may be prescribed by specialists.

Level
S (zonal, special and national hospitals)
Category
Antineoplastics, Immunosuppressives and Immunomodulators
Listed forms
Injection 40mg/0.8mL, 10mg / 0.2mL
Page
NEMLIT, p. 14
Who may prescribe at each NEMLIT level (STG/NEMLIT 7th edition, Part I, Table 1). Levels listed for this medicine are highlighted.
LevelFacilityWho may prescribe
ADispensarySpecialist, Medical Officer, Dental Officer, Assistant Medical Officer, Clinical Officer, Assistant Clinical Officer
BHealth centreSpecialist, Medical Officer, Dental Officer, Assistant Medical Officer, Clinical Officer
CCouncil or district hospitalSpecialist, Medical Officer, Dental Officer, Assistant Medical Officer
DRegional referral hospitalSpecialist, Medical Officer, Dental Officer
S (listed)Zonal, special and national hospitalsSpecialist

A medicine is listed from the lowest facility level where it should be available.

Where is adalimumab in the Standard Treatment Guidelines?

The Standard Treatment Guidelines (7th edition, 2026) mention adalimumab in 8 or more sections, most often section 10.3.1.1 Diseases of the Intestine > Inflammatory Bowel Diseases > Ulcerative Colitis (UC) (p. 239). See the STG for treatment details.

  • 10.3.1.1 Diseases of the Intestine > Inflammatory Bowel Diseases > Ulcerative Colitis (UC), p. 239
  • 10.3.1.2 Diseases of the Intestine > Inflammatory Bowel Diseases > Crohn’s Disease, p. 239
  • 13.7.1 Papulosquamous and Lichenoid Disorder > Psoriasis, p. 324
  • 26.1.1 Inflammatory Arthritis > Rheumatoid Arthritis (RA), p. 711
  • 26.1.2 Inflammatory Arthritis > Psoriatic Arthritis (PsA), p. 713
  • 26.1.3 Inflammatory Arthritis > Axial Spondyloarthritis, p. 714
  • 26.1.5 Inflammatory Arthritis > Enteropathic Arthritis (Associated with IBD), p. 717
  • 26.6 Juvenile Idiopathic Arthritis (JIA), p. 728

Sections that mention Adalimumab, most mentions first. Positions only: see the STG for treatment details.

Related medicines

All antineoplastics, immunosuppressives and immunomodulators on the NEMLIT

Sources

  • Standard Treatment Guidelines and National Essential Medicines List (STG/NEMLIT), 7th edition, 2026, Ministry of Health, United Republic of Tanzania

Page last updated

STG positions are section numbers and printed page numbers only.

This page supports licensed prescribers and pharmacists. It is not medical advice and does not replace the Standard Treatment Guidelines, the product information or professional judgement. Prices and stock change often: confirm with the pharmacy.

For licensed prescribers and pharmacists. Not medical advice. Check the Standard Treatment Guidelines before prescribing.